Please try another search
For the fiscal year ended 31 March 2018, RichPharmaceuticals Inc revenues increased from $0K to $115K.Net loss decreased 48% to $1.7M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Lower net loss reflectsChange in value of derivative liability increase from $1.1M(expense) to $1.5M (income), Gain (Loss) on extinguishmentof debt decrease from $70K (expense) to $213K (income).
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0.12 | 0 |
Gross Profit | ||||
Operating Income | -0.31 | -0.33 | -0.22 | -0.26 |
Net Income | -1.24 | 0.06 | 1.8 | -2.3 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Total Assets | 0.04 | 0.04 | 0.06 | 0.02 |
Total Liabilities | 6.4 | 5.25 | 5.36 | 7.53 |
Total Equity | -6.36 | -5.21 | -5.31 | -7.51 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -0.51 | -0.37 | -0.29 | -0.18 |
Cash From Investing Activities | -0.02 | -0.02 | -0.02 | -0.01 |
Cash From Financing Activities | 0.49 | 0.35 | 0.3 | 0.14 |
Net Change in Cash | -0.03 | -0.04 | -0.02 | -0.04 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review